Lista de obras - Cristiano Noto - Dominio Público Uruguay

A symptom combination predicting treatment-resistant schizophrenia - A strategy for real-world clinical practice

artículo científico publicado en 2020

Accessing Gene Expression in Treatment-Resistant Schizophrenia.

artículo científico publicado en 2018

Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis

scientific article published on 26 December 2018

Angiotensin converting enzyme activity is positively associated with IL-17a levels in patients with schizophrenia

artículo científico publicado en 2015

Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder

artículo científico publicado en 2018

Association of biomarkers and depressive symptoms in schizophrenia

artículo científico publicado en 2011

Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls

artículo científico publicado en 2017

Changes in gene expression and methylation in the blood of patients with first-episode psychosis

artículo científico publicado en 2014

Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia.

artículo científico publicado en 2013

DGCR2 influences cortical thickness through a mechanism independent of schizophrenia pathogenesis

scientific article published on 27 February 2019

Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Naïve First Episode Psychosis

artículo científico publicado en 2015

Determinants of adherence to treatment in first-episode psychosis: a comprehensive review

artículo científico

Disorganized Symptoms Predicted Worse Functioning Outcome in Schizophrenia Patients with Established Illness

artículo científico publicado en 2015

Effects of depression on the cytokine profile in drug naïve first-episode psychosis.

artículo científico publicado en 2015

Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis.

artículo científico publicado en 2014

Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: a follow-up study in antipsychotic-naïve patients with first-episode psychosis.

artículo científico publicado en 2014

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA.

artículo científico publicado en 2018

Factor structure of the Positive and Negative Syndrome Scale (PANSS) in Brazil: convergent validation of the Brazilian version

artículo científico publicado en 2014

Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls.

artículo científico publicado en 2015

Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages

article

Hair cortisol in drug-naïve first-episode individuals with psychosis

artículo científico publicado en 2016

High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance

artículo científico publicado en 2015

How challenging is to manage agitated patients?

artículo científico publicado en 2019

Impact of duration of untreated psychosis in short-term response to treatment and outcome in antipsychotic naïve first-episode psychosis

artículo científico publicado en 2019

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia.

artículo científico

Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-naïve patients with first-episode psychosis

artículo científico publicado en 2015

Investigating brain structural patterns in first episode psychosis and schizophrenia using MRI and a machine learning approach.

artículo científico publicado en 2018

LINE-1 hypomethylation is associated with poor risperidone response in a first episode of psychosis cohort

artículo científico publicado en 2020

Leukocyte telomere length variation in different stages of schizophrenia

artículo científico publicado en 2017

Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis

scientific article published on 27 June 2015

Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia

artículo científico publicado en 2019

Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naïve first-episode psychosis patients before and after antipsychotic treatment

artículo científico publicado en 2013

New evidence in support of staging approaches in schizophrenia: Differences in clinical profiles between first episode, early stage, and late stage

artículo científico publicado en 2016

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS.

artículo científico publicado en 2018

Omics-based depression and inflammation research

artículo científico publicado en 2015

Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone

artículo científico publicado en 2015

PRODH polymorphisms, cortical volumes and thickness in schizophrenia

artículo científico publicado en 2014

Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.

artículo científico

Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway.

artículo científico publicado en 2017

Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort

scientific article published on 31 August 2018

Recognition of bipolar disorder type I before the first manic episode: challenges and developments.

artículo científico publicado en 2013

Schneider's first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis

scientific article published on 01 January 2020

Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls

artículo científico publicado en 2015

Shorter leukocyte telomere length in patients at ultra high risk for psychosis

artículo científico publicado en 2017

Structural covariance in schizophrenia and first-episode psychosis: An approach based on graph analysis

artículo científico publicado en 2015

T176. REDUCED WHITE MATTER ‘CONNECTIVITY’ IN THE SPLENIUM OF THE CORPUS CALLOSUM IN TREATMENT-RESISTANT SCHIZOPHRENIA.

artículo científico publicado en 2018

Targeting the inflammatory pathway as a therapeutic tool for major depression.

artículo científico publicado en 2014

The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia

scientific article published on 31 August 2019

The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder

artículo científico

Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research

artículo científico

Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese.

artículo científico publicado en 2013

Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia

artículo científico publicado en 2016

What are the PANSS items most related with global improvements in patients with schizophrenia? Toward a reduced version of the PANSS.

artículo científico publicado en 2014

Lista de obras de Cristiano Noto

A symptom combination predicting treatment-resistant schizophrenia - A strategy for real-world clinical practice

Accessing Gene Expression in Treatment-Resistant Schizophrenia.

Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis

Angiotensin converting enzyme activity is positively associated with IL-17a levels in patients with schizophrenia

Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder

Association of biomarkers and depressive symptoms in schizophrenia

Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls

Changes in gene expression and methylation in the blood of patients with first-episode psychosis

Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia.

DGCR2 influences cortical thickness through a mechanism independent of schizophrenia pathogenesis

Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Naïve First Episode Psychosis

Determinants of adherence to treatment in first-episode psychosis: a comprehensive review

Disorganized Symptoms Predicted Worse Functioning Outcome in Schizophrenia Patients with Established Illness

Effects of depression on the cytokine profile in drug naïve first-episode psychosis.

Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis.

Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: a follow-up study in antipsychotic-naïve patients with first-episode psychosis.

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA.

Factor structure of the Positive and Negative Syndrome Scale (PANSS) in Brazil: convergent validation of the Brazilian version

Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls.

Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages

Hair cortisol in drug-naïve first-episode individuals with psychosis

High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance

How challenging is to manage agitated patients?

Impact of duration of untreated psychosis in short-term response to treatment and outcome in antipsychotic naïve first-episode psychosis

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia.

Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-naïve patients with first-episode psychosis

Investigating brain structural patterns in first episode psychosis and schizophrenia using MRI and a machine learning approach.

LINE-1 hypomethylation is associated with poor risperidone response in a first episode of psychosis cohort

Leukocyte telomere length variation in different stages of schizophrenia

Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis

Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia

Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naïve first-episode psychosis patients before and after antipsychotic treatment

New evidence in support of staging approaches in schizophrenia: Differences in clinical profiles between first episode, early stage, and late stage

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS.

Omics-based depression and inflammation research

Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone

PRODH polymorphisms, cortical volumes and thickness in schizophrenia

Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.

Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway.

Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort

Recognition of bipolar disorder type I before the first manic episode: challenges and developments.

Schneider's first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis

Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls

Shorter leukocyte telomere length in patients at ultra high risk for psychosis

Structural covariance in schizophrenia and first-episode psychosis: An approach based on graph analysis

T176. REDUCED WHITE MATTER ‘CONNECTIVITY’ IN THE SPLENIUM OF THE CORPUS CALLOSUM IN TREATMENT-RESISTANT SCHIZOPHRENIA.

Targeting the inflammatory pathway as a therapeutic tool for major depression.

The Role of Aberrations in the Immune-Inflammatory Response System (IRS) and the Compensatory Immune-Regulatory Reflex System (CIRS) in Different Phenotypes of Schizophrenia: the IRS-CIRS Theory of Schizophrenia

The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder

Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research

Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese.

Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia

What are the PANSS items most related with global improvements in patients with schizophrenia? Toward a reduced version of the PANSS.